These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 17336621)

  • 41. Efficacy of tumor necrosis factor alpha blockade for enthesitis in spondylarthropathy: comment on the article by Marzo-Ortega et al.
    Olivieri I; Padula A; Scarano E
    Arthritis Rheum; 2002 Dec; 46(12):3396-8; author reply 3398. PubMed ID: 12483753
    [No Abstract]   [Full Text] [Related]  

  • 42. Lack of efficacy of etanercept in Sjögren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation.
    Moutsopoulos NM; Katsifis GE; Angelov N; Leakan RA; Sankar V; Pillemer S; Wahl SM
    Ann Rheum Dis; 2008 Oct; 67(10):1437-43. PubMed ID: 18198195
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of necrobiosis lipoidica with the tumor necrosis factor antagonist etanercept.
    Zeichner JA; Stern DW; Lebwohl M
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S120-1. PubMed ID: 16488322
    [No Abstract]   [Full Text] [Related]  

  • 44. [Development of systemic lupus erythematosus with focal proliferative lupus nephritis during anti-TNF-alpha therapy for psoriatic arthritis].
    Haake H; Köneke J; Amann K; vom Dahl J; Janssen U
    Med Klin (Munich); 2007 Oct; 102(10):852-7. PubMed ID: 17928969
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lymphoedema: a rare complication of inflammatory rheumatism. Successful treatment with etanercept.
    Doffoël-Hantz V; Sparsa A; Verbeke S; Tricard MJ; Bonnetblanc JM; Bédane C
    Eur J Dermatol; 2007; 17(4):337-8. PubMed ID: 17540645
    [No Abstract]   [Full Text] [Related]  

  • 46. Safety of etanercept therapy in a patient with psoriasis, Down's syndrome and concomitant hepatitis C virus infection.
    Alcaide AJ; Barrera MV; Habicheyn S; López N; Mendiola MV; Herrera E
    J Eur Acad Dermatol Venereol; 2008 Dec; 22(12):1514-6. PubMed ID: 18355196
    [No Abstract]   [Full Text] [Related]  

  • 47. Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept).
    Yazisiz V; Avci AB; Erbasan F; Yildirim B; Terzioğlu E
    Colorectal Dis; 2008 Nov; 10(9):953-4. PubMed ID: 18294265
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Successful treatment of pemphigus vulgaris with etanercept in four patients.
    Shetty A; Marcum CB; Glass LF; Carter JD
    J Drugs Dermatol; 2009 Oct; 8(10):940-3. PubMed ID: 19852124
    [TBL] [Abstract][Full Text] [Related]  

  • 49. TNF-alpha inhibition for potential therapeutic modulation of SARS coronavirus infection.
    Tobinick E
    Curr Med Res Opin; 2004 Jan; 20(1):39-40. PubMed ID: 14741070
    [No Abstract]   [Full Text] [Related]  

  • 50. Remission of photosensitivity following treatment of psoriasis vulgaris with tumour necrosis factor inhibitors.
    Viguier M; Jeanmougin M; Begon E; Verola O; Dubertret L; Bachelez H
    Br J Dermatol; 2007 Sep; 157(3):625-7. PubMed ID: 17596163
    [No Abstract]   [Full Text] [Related]  

  • 51. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation.
    Theodossiadis PG; Markomichelakis NN; Sfikakis PP
    Retina; 2007; 27(4):399-413. PubMed ID: 17420690
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Etanercept provides a more physiological approach in the treatment of psoriasis.
    Altomare G; Ayala F; Berardesca E; Chimenti S; Giannetti A; Girolomoni G; Lotti T; Martini P; Peserico A; Guerra AP; Vena GA
    Dermatol Ther; 2008 Oct; 21 Suppl 2():S1-14. PubMed ID: 18837727
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tumor necrosis factor alpha in refractory asthma.
    Oliveri C; Polosa R
    N Engl J Med; 2006 May; 354(19):2074-5; author reply 2074-5. PubMed ID: 16687725
    [No Abstract]   [Full Text] [Related]  

  • 54. Chronic viral hepatitis and TNF-alpha blockade.
    Raftery G; Griffiths B; Kay L; Kane D
    Rheumatology (Oxford); 2007 Aug; 46(8):1381; author reply 1381-2. PubMed ID: 17567635
    [No Abstract]   [Full Text] [Related]  

  • 55. The tumor-necrosis-factor-associated periodic syndrome, the brain, and tumor-necrosis-factor-alpha antagonists.
    Wildemann B; Rudofsky G; Kress B; Jarius S; Konig F; Schwenger V
    Neurology; 2007 May; 68(20):1742-4. PubMed ID: 17360963
    [No Abstract]   [Full Text] [Related]  

  • 56. Better look (and think) twice--TNF-alpha-inhibition and multiple sclerosis.
    Scheid R
    Clin Neurol Neurosurg; 2013 Jul; 115(7):1195-6. PubMed ID: 23026417
    [No Abstract]   [Full Text] [Related]  

  • 57. Familial Mediterranean fever successfully treated with etanercept.
    Mor A; Pillinger MH; Kishimoto M; Abeles AM; Livneh A
    J Clin Rheumatol; 2007 Feb; 13(1):38-40. PubMed ID: 17278949
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Increase in plasma levels of adiponectin after administration of anti-tumor necrosis factor agents in patients with rheumatoid arthritis.
    Nagashima T; Okubo-Fornbacher H; Aoki Y; Kamata Y; Kimura H; Kamimura T; Nara H; Iwamoto M; Yoshio T; Okazaki H; Minota S
    J Rheumatol; 2008 May; 35(5):936-8. PubMed ID: 18464318
    [No Abstract]   [Full Text] [Related]  

  • 59. Lack of efficacy of etanercept in acrodermatitis continua of Hallopeau.
    Adişen E; Oztaş M; Gürer MA
    Int J Dermatol; 2007 Nov; 46(11):1205-7. PubMed ID: 17988345
    [No Abstract]   [Full Text] [Related]  

  • 60. Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade.
    van Eijk IC; Peters MJ; Serné EH; van der Horst-Bruinsma IE; Dijkmans BA; Smulders YM; Nurmohamed MT
    Ann Rheum Dis; 2009 Mar; 68(3):362-6. PubMed ID: 18390569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.